Clinical outcomes of sirolimus-eluting stenting after rotational atherectomy.
BACKGROUND
The efficacy of drug-eluting stents after rotational atherectomy (ROTA) has not been clarified.


RESULTS
The 704 consecutive patients who underwent percutaneous coronary intervention (PCI) with a sirolimus-eluting stent (SES) (79 with and 625 without ROTA) were enrolled. The 2-year clinical outcome of these patients was compared with that of a group of 1,123 consecutive patients treated with bare-metal stents (BMS) (144 with and 979 without ROTA). At 2 years after index PCI, the use of SES after ROTA was associated with a lower crude incidence of major adverse cardiac events (MACE) than were BMS after ROTA (30.1% vs 43.1%, P=0.024). The difference was mainly derived from the reduction in target lesion revascularization (TLR) (25.0% vs 39.1%, P=0.022). After adjusting for confounders, ROTA-SES was associated with a reduction in MACE and TLR, with a similar hazard ratio to the non-ROTA group only with SES implantation. In a subgroup of dialysis patients, the incidence of TLR after ROTA with SES and BMS was similarly high.


CONCLUSIONS
The use of SES after ROTA is an appropriate method for selected hard lesions, but has a limited effect in dialysis patients, even after lesion preparation with ROTA.
Tamekiyo
Hiromichi
H
Department of Cardiology, Tsuchiya General Hospital, Hiroshima, Japan. tame0214@yahoo.co.jp
Hayashi
Yasuhiko
Y
Toyofuku
Mamoru
M
Ueda
Hironori
H
Sakuma
Tadamichi
T
Okimoto
Tomokazu
T
Otsuka
Masaya
M
Imazu
Michinori
M
Kihara
Yasuki
Y
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D017225:Atherectomy, Coronary; D002114:Calcinosis / Q000628:therapy; D003324:Coronary Artery Disease / Q000628:therapy; D023903:Coronary Restenosis; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D020123:Sirolimus